SCHEMBL19328643

SCHEMBL19328643

COc1cccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 2/20 0.37
MAPT P10636 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
AHR P35869 1/20 0.36
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
CSF1R P07333 2/20 0.35
P4HTM Q9NXG6 1/20 0.35
PTPN11 Q06124 1/20 0.35
HPGD P15428 1/20 0.34
ATR Q13535 1/20 0.34
CDK9 P50750 1/20 0.34
HPGDS O60760 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL86605 0.90 KDM4E (0.41) PTAFRMAPTSLC6A2SLC6A4SLC6A3
SCHEMBL21096736 0.87 MAPT (0.40) PTAFRMAPTMEN1KMT2AKDR
SCHEMBL83347 0.85 MAPT (0.50) MAPTPOLBSMN1; SMN2KDM4E
SCHEMBL82489 0.84 CCNC (0.39) PTAFRMAPTMEN1KMT2AHPGDS
SCHEMBL29475025 0.84 CCNC (0.39) PTAFRMAPTMEN1KMT2AHPGDS
SCHEMBL19346312 0.83 MAPT (0.34) PTAFRMAPTMEN1KMT2APDGFRB
SCHEMBL17727593 0.82 MAPT (0.36) PTAFRMAPTMEN1KMT2AKDR
SCHEMBL22864303 0.82 MAPT (0.36) PTAFRMAPTMEN1KMT2AKDR
SCHEMBL86828 0.82 KMT2A (0.40) MAPTMEN1KMT2AHPGDPOLB
SCHEMBL87060 0.81 POLB (0.40) MAPTMEN1KMT2AKDRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426657-B1 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES Bayer Pharma AG (DE) 2022-07-13 EP disclosed
EP-3426657-B1 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES Bayer Pharma AG (DE) 2022-07-13 EP disclosed
CN-108884098-B 2-amino-N- [ 7-methoxy-2, 3-dihydroimidazo [1,2-c ] quinazolin-5-yl ] pyrimidine-5-carboxamides 拜耳制药股份公司 2021-09-14 CN disclosed
CN-108884098-B 2-amino-N- [ 7-methoxy-2, 3-dihydroimidazo [1,2-c ] quinazolin-5-yl ] pyrimidine-5-carboxamides 拜耳制药股份公司 2021-09-14 CN disclosed
US-10844066-B2 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-11-24 US disclosed
US-10844066-B2 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-11-24 US disclosed
US-20190092775-A1 2-AMINO-N- [7-METHOXY-2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE-5-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-03-28 US disclosed
US-20190092775-A1 2-AMINO-N- [7-METHOXY-2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE-5-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-03-28 US disclosed
EP-3426657-A1 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES Bayer Pharma Aktiengesellschaft (DE) 2019-01-16 EP disclosed
EP-3426657-A1 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES Bayer Pharma Aktiengesellschaft (DE) 2019-01-16 EP disclosed
WO-2017153220-A1 2—AMINO—N— [7—METHOXY—2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE—5—CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-14 WO disclosed
WO-2017153220-A1 2—AMINO—N— [7—METHOXY—2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE—5—CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844066-B2 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides PIK3CA, PIK3CD, PIK3CB PTAFR 550/4885MAPT 3263/4885SLC6A2 4508/4885
US-20190092775-A1 2-AMINO-N- [7-METHOXY-2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE-5-CARBOXAMIDES PIK3CA, PIK3CD, PIK3CB PTAFR 550/4885MAPT 3263/4885SLC6A2 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.